Asahi shares mark weekly slide after cyberattack halts production
Romeo R. Dizon, Chief Financial Officer of Iridex Corp (NASDAQ:IRIX), acquired 1,450 shares of common stock on September 12, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The medical technology company, currently valued at $22 million, has shown strong momentum with positive returns over the past three months. According to InvestingPro analysis, the stock appears undervalued relative to its Fair Value.
The shares were purchased in two transactions, with prices ranging from $1.36 to $1.37, totaling $1,974. With InvestingPro showing 8 additional key insights about IRIX’s financial health and valuation, subscribers can access comprehensive analysis through the Pro Research Report. Following the transactions, Dizon directly owns 61,950 shares of Iridex.
In other recent news, Iridex Corporation reported its second-quarter earnings for 2025, surpassing analyst expectations. The company achieved an earnings per share (EPS) of -$0.06, outperforming the projected -$0.09. Additionally, Iridex’s revenue reached $13.6 million, exceeding the anticipated $13.1 million. In another development, Iridex announced it has regained compliance with Nasdaq’s continued listing requirements. This follows a previous non-compliance notification received on May 14, 2025, due to a quarterly report that did not meet Nasdaq Listing Rule 5550(b) standards. These recent developments indicate significant progress for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.